Friday 6 November 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
65.55
0.12
−0.18%
Follow PTCT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(104.75%) | 101.97% | 20.64% | 61.08% | |
Piotroski F-Score |
7 | 1 | 2 | 3 | |
| 29.66% | (6.76%) | (1.30%) | (3.62%) | ||
ROIC |
121.13% | (6.74%) | 15.16% | 17.66% | |
Return on Tangible Assets |
50.16% | (13.50%) | (2.02%) | (5.85%) | |
Average Days of Receivables |
38.30 | 97.05 | 86.49 | 75.20 | |
Free Cash Flow per Share |
8.83 | (5.85) | (3.62) | (3.10) | |
Free Cash Flow |
702.41 | (482.67) | (300.25) | (259.16) | |
Capital Expenditures |
(8.79) | (264.72) | (269.74) | (269.64) | |
| Other line items | |||||
Cash ROIC |
16.19% | (11.16%) | (6.03%) | (5.42%) | |
Accounts Receivable Turnover |
10.18 | 3.84 | 4.64 | 5.24 | |
Accounts Payable Turnover |
0.14 | 0.20 | 0.20 | 0.21 | |
Inventory Turnover |
0.91 | 1.28 | 1.13 | 0.97 | |
Average Days of Payables |
2,960.12 | 1,837.65 | 1,973.96 | 2,047.99 | |
Days of Inventory on Hand |
618.36 | 443.59 | 471.76 | 507.95 | |
Tax Rate |
(0.02) | (0.21) | (0.43) | 0.25 | |
Research and Development Expense of Revenue |
26.31% | 54.06% | 42.95% | 37.95% | |
Selling, General and Administrative Expense of Revenue |
20.06% | 42.60% | 34.47% | 29.75% | |
Share Based Compensation of Revenue |
4.31% | 9.66% | 8.39% | 7.71% | |
Interest Coverage |
5.69 | (0.35) | 0.68 | 0.74 | |
Operating CF/Net income |
1.04 | 1.17 | 0.79 | (0.10) | |
Depreciation/Fixed assets |
0.40 | 0.55 | 0.72 | 0.89 | |
Capex/Depreciation |
(0.40) | (9.05) | (7.25) | (6.11) | |
Revenue per Share |
21.76 | 10.02 | 12.15 | 13.84 | |
Operating CF per Share |
8.94 | (2.64) | (0.37) | 0.13 | |
Capex per Share |
(0.11) | (3.21) | (3.25) | (3.23) | |
Capex to Sales |
0.01 | 0.32 | 0.27 | 0.23 |
Columns are period end dates · fundamentals updated 6 Nov 2026